Medical researchers advance diagnostic tools for rare diseases and cancer risks

New research and clinical strategies are improving the diagnostic capabilities for rare conditions and inherited cancer risks. Researchers from Queen Mary University of London, the Berlin Institute of Health at Charité, and Genomics England have demonstrated that combining blood proteomics—the measurement of nearly 1,500 proteins—with genomic data can resolve uncertain genetic findings. This approach helps identify diagnoses for patients who remained undiagnosed after standard genome sequencing.

In a separate development, the BRCA-DIRECT genetic testing pathway is being implemented to identify inherited breast cancer risks more efficiently. A study involving over 3,500 patients found that 4.7% carried potentially harmful genetic profiles. This streamlined approach, commissioned by NHS England, aims to reduce the burden on genetic services while increasing the identification of mutations in genes such as BRCA1, BRCA2, and PALB2.

Additionally, data from the Undiagnosed Diseases Network (UDN) highlights the effectiveness of integrating clinical expertise with advanced research strategies. The UDN reported a diagnostic rate of 22.1% for its second cohort, noting that many diagnoses required research efforts that go beyond standard clinical care, such as the reanalysis of sequencing data and case matching.